Skip to Content
MDPIMDPI
ARMAdvances in Respiratory Medicine
PDF
  • Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.
  • Case Report
  • Open Access

31 October 2008

Long-Term Remission after Erlotinib Therapy in an Elderly Patient with Advanced Non-small Cell Lung Cancer. Case Report and Conclusions for Clinical Practice

,
,
and
1
Department of Oncology, Military Institute of Medicine in Warsaw, 128 Szaserów St., 00-909 Warsaw, Poland
2
Department of Biology and Genetics, Medical University of Gdańsk, 80-210 Gdańsk, Poland
3
Department of Pathology, Military Institute of Medicine in Warsaw, 128 Szaserów St., 00-909 Warsaw, Poland
*
Author to whom correspondence should be addressed.
Adv. Respir. Med.2008, 76(6), 451-455;https://doi.org/10.5603/ARM.27862
Version Notes
Order Reprints

Abstract

Small molecule tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR)—gefitinib and erlotinib—have recently been used as a therapeutic option in advanced non-small cell lung cancer (NSCLC) patients relapsing after first- or second-line chemotherapy. We report here a case of long-term remission in an elderly, non-smoking woman with advanced NSCLC after chemotherapy failure, who was selected for erlotinib therapy using demographic and clinical criteria. Based on this example and on the literature data we discuss the need for careful patient selection for this new therapeutic method.

Article Metrics

Citations

Article Access Statistics

Journal Statistics
Multiple requests from the same IP address are counted as one view.
Comparison of Outpatient and Inpatient Costs of Moderate and Severe Exacerbations of Chronic Obstructive Pulmonary Disease in Poland
Previous
The Usefulness of Scintigraphic Assessment of Thoracic Splenosis—A Case Report
Next